Reference pricing changes to cost industry €650 million in Spain
This article was originally published in Scrip
Not long after taking power, Spain's new government has signed into law changes to the reference pricing system, which will cost the pharmaceutical industry some €650 million. The new changes will exacerbate already tough market conditions and add to government measures introduced in 2011 aimed at shaving €2.4 billion off the drugs bill, says Farmaindustria, the association representing the R&D-based pharmaceutical industry.
You may also be interested in...
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.
Intellectual property rights are under the microscope as countries prepare to provide affordable and timely access to pandemic technologies.